Investor Presentaiton

Key messages 1 Expanding opportunity Industry fragmentation and increasing drug development complexity driving royalty creation 2 Significant capital needs >$1 trillion of capital required to fund biopharma innovation over the next decade 3 Innovative funding Synthetic royalties broaden opportunity set to entire universe of late-stage drug development 4 Facilitating M&A Trusted partner enabling M&A through full suite of funding solutions 5 Differentiated sourcing Proprietary sourcing and relationships provide powerful competitive advantage ROYALTY PHARMA 31

View entire presentation